Clinical trial
A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE)
NCT04515394 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE)
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 28, 2021
- Completion date
- March 31, 2022
- Enrollment
- 3 (actual)
- Sites
- 65
Conditions
As the registry lists them; a condition with its own page is linked.